These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28410123)

  • 1. Poly(ADP-Ribose) polymerase 1: a therapeutic hope in gynecologic cancers.
    Rajawat J; Shukla N; Mishra DP
    Front Biosci (Schol Ed); 2017 Jun; 9(3):343-356. PubMed ID: 28410123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
    Rajawat J; Shukla N; Mishra DP
    Med Res Rev; 2017 Nov; 37(6):1461-1491. PubMed ID: 28510338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
    Henning RJ; Bourgeois M; Harbison RD
    Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
    Li N; Wang Y; Deng W; Lin SH
    Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly (ADP-ribose) polymerase-1 as a promising drug target for neurodegenerative diseases.
    Thapa K; Khan H; Sharma U; Grewal AK; Singh TG
    Life Sci; 2021 Feb; 267():118975. PubMed ID: 33387580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updates in the Use of Targeted Therapies for Gynecologic Cancers.
    Cantillo E; Blanc-Durand F; Leary A; Slomovitz BM; Fuh K; Washington C
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e438582. PubMed ID: 38788185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A New Opportunity for "Old" Molecules: Targeting PARP1 Activity through a Non-Enzymatic Mechanism.
    Iglesias P; Seoane M; Golán-Cancela I; Fraga M; Arce VM; Costoya JA
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly(ADP-ribose) polymerase inhibitors activate the p53 signaling pathway in neural stem/progenitor cells.
    Okuda A; Kurokawa S; Takehashi M; Maeda A; Fukuda K; Kubo Y; Nogusa H; Takatani-Nakase T; Okuda S; Ueda K; Tanaka S
    BMC Neurosci; 2017 Jan; 18(1):14. PubMed ID: 28095779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement.
    Martín-Guerrero SM; León J; Quiles-Perez R; Belmonte L; Martin-Oliva D; Ruiz-Extremera Á; Salmerón J; Muñoz-Gámez JA
    Curr Med Chem; 2017; 24(20):2156-2173. PubMed ID: 28302009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
    Jain PG; Patel BD
    Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.
    Wang YQ; Wang PY; Wang YT; Yang GF; Zhang A; Miao ZH
    J Med Chem; 2016 Nov; 59(21):9575-9598. PubMed ID: 27416328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?
    Lightfoot M; Montemorano L; Bixel K
    Curr Oncol Rep; 2020 Feb; 22(3):29. PubMed ID: 32067102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Application of PARP Inhibitors in Neuro-Oncology.
    Ning J; Wakimoto H
    Trends Cancer; 2020 Feb; 6(2):147-159. PubMed ID: 32061304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials.
    Crafton SM; Bixel K; Hays JL
    Gynecol Oncol; 2016 Sep; 142(3):588-96. PubMed ID: 27168003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and evaluation of potential inhibitors for poly(ADP-ribose) polymerase members 1 and 14.
    Kam CM; Tauber AL; Levonis SM; Schweiker SS
    Future Med Chem; 2020 Dec; 12(24):2179-2190. PubMed ID: 33225736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly(ADP-ribose) polymerase inhibition: past, present and future.
    Curtin NJ; Szabo C
    Nat Rev Drug Discov; 2020 Oct; 19(10):711-736. PubMed ID: 32884152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
    Turk AA; Wisinski KB
    Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.